(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 March 2009 (12.03.2009)

PCT

(10) International Publication Number
WO 2009/030368 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/02* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/EP2008/006833

(22) International Filing Date: 20 August 2008 (20.08.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07017337.2 5 September 2007 (05.09.2007) EP

(71) Applicants *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). **GLYCART BIOTECHNOLOGY AG** [CH/CH]; Wagistrasse 18, CH-8952 Schlieren-Zuerich (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FRIESS, Thomas** [DE/DE]; St. Martin-Strasse 8a, 86911 Diessen-Dettenhofen (DE). **KLEIN, Christian** [DE/DE]; Moraenenweg 5, 82393 Iffeldorf (DE). **UMANA, Pablo** [CH/CH]; Milchbuckstrasse 3, CH-8057 Zuerich (CH).

(74) Agent: **BURGER, Alexander**; Roche Diagnostics GmbH, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*

[Continued on next page]

(54) Title: COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES

Fig. 1



(57) Abstract: The present application is directed to the combination therapy of a type I and a type II anti-CD20 antibody for the treatment of cancer, especially of CD20 expressing cancer.

WO 2009/030368 A1

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*